Palvella Therapeutics Stock (NASDAQ:PVLA)

Financials Chart

Previous Close

$23.93

52W Range

$6.20 - $29.27

50D Avg

$22.78

200D Avg

$16.86

Market Cap

$268.86M

Avg Vol (3M)

$70.67K

Beta

-23.17

Div Yield

-

PVLA Company Profile

Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. Its lead product candidate is QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin) that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is based in Wayne, Pennsylvania.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

14

IPO Date

Jan 02, 2015

Website

PVLA Performance

PVLA Financial Summary

	Dec 24	Dec 23	Dec 22
Revenue	-	-	-
Operating Income	$-14.10M	$-11.87M	$-18.04M
Net Income	$-17.43M	$18.69M	$-27.55M
EBITDA	$-13.12M	$18.69M	$-18.04M
Basic EPS	$-7.83	$1.60	$-2.46
Diluted EPS	$-7.83	$1.60	$-2.46

Fiscal year ends in Dec 24 | Currency in USD